GlobeStar Therapeutics Corp
company.status.inactiveCIK 1502152fmd_1JQFY6XS4EWS35JA953MKS2FW3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Sep 16, 2010 to Jun 30, 2024, 55 periods
Latest annual · FY2020
Millions- Total revenues
- 0
- Gross profit
- (0)
- Operating income
- (2)
- Net income
- (2)
Latest quarter · Q3 FY2024
Millions- Operating income
- (0)
- Net income
- (0)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2018 to FY2023
- n/m
GlobeStar Therapeutics Corp financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Operating income | -$1.9 million | -$1.3 million | 10-K 2024-01-19 · proof | |
| Net income | -$1.9 million | -$1.5 million | 10-K 2024-01-19 · proof | |
| Cash from operating activities | -$205,760 | -$326,995 | 10-K 2024-01-19 · proof | |
| Total liabilities | $1.4 million | $1.2 million | +19% | 10-K 2024-01-19 · proof |
| Cash and cash equivalents | $0 | $6,365 | -100% | 10-K 2024-01-19 · proof |
- What was GlobeStar Therapeutics Corp's operating income in fiscal 2023?
- GlobeStar Therapeutics Corp reported operating income of -$1.9 million for fiscal 2023 (the year ended Sep 30, 2023), against -$1.3 million the year before. Source: the 10-K filed with the SEC on Jan 19, 2024. SEC
- What was GlobeStar Therapeutics Corp's net income in fiscal 2023?
- GlobeStar Therapeutics Corp reported net income of -$1.9 million for fiscal 2023 (the year ended Sep 30, 2023), against -$1.5 million the year before. Source: the 10-K filed with the SEC on Jan 19, 2024. SEC
- What was GlobeStar Therapeutics Corp's cash from operating activities in fiscal 2023?
- GlobeStar Therapeutics Corp reported cash from operating activities of -$205,760 for fiscal 2023 (the year ended Sep 30, 2023), against -$326,995 the year before. Source: the 10-K filed with the SEC on Jan 19, 2024. SEC
- What are GlobeStar Therapeutics Corp's total liabilities?
- As of Sep 30, 2023, GlobeStar Therapeutics Corp reported total liabilities of $1.4 million, against $1.2 million a year earlier (+19%). Source: the 10-K filed with the SEC on Jan 19, 2024. SEC
- What are GlobeStar Therapeutics Corp's cash and cash equivalents?
- As of Sep 30, 2023, GlobeStar Therapeutics Corp reported cash and cash equivalents of $0, against $6,365 a year earlier (-100%). Source: the 10-K filed with the SEC on Jan 19, 2024. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1502152&period_type=annual&limit=5"Information only, not investment advice.